Daiwa Securities Group Inc. decreased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 19.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,858 shares of the biopharmaceutical company’s stock after selling 2,777 shares during the period. Daiwa Securities Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,791,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. Wrapmanager Inc. raised its stake in Regeneron Pharmaceuticals by 9.9% in the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock valued at $497,000 after buying an additional 130 shares during the period. Raymond James Financial Services Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 4.7% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 141 shares during the period. Traynor Capital Management Inc. raised its stake in Regeneron Pharmaceuticals by 9.8% in the second quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock valued at $572,000 after buying an additional 145 shares during the period. Atria Investments LLC raised its stake in Regeneron Pharmaceuticals by 10.9% in the second quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 147 shares during the period. Finally, MUFG Securities EMEA plc raised its stake in Regeneron Pharmaceuticals by 1.7% in the second quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock valued at $3,116,000 after buying an additional 152 shares during the period. Hedge funds and other institutional investors own 66.06% of the company’s stock.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 2,000 shares of the firm’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total transaction of $784,520.00. Following the transaction, the director now owns 2,000 shares in the company, valued at approximately $784,520. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,052 shares of company stock worth $44,651,762. Corporate insiders own 12.42% of the company’s stock.
Regeneron Pharmaceuticals stock opened at $357.61 on Wednesday. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $432.50. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62. The firm has a market cap of $38.10 billion, a price-to-earnings ratio of 26.67, a P/E/G ratio of 1.18 and a beta of 1.34.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the Zacks’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The firm had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. During the same quarter last year, the company earned $3.99 EPS. The company’s revenue was up 10.8% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals Inc will post 19.31 earnings per share for the current fiscal year.
A number of equities analysts have recently weighed in on REGN shares. TheStreet upgraded Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Wednesday, July 25th. Cowen reiterated a “hold” rating and set a $385.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Robert W. Baird lowered Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday, August 3rd. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, October 19th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $340.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, July 24th. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $410.95.
TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Daiwa Securities Group Inc.” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/regeneron-pharmaceuticals-inc-regn-shares-sold-by-daiwa-securities-group-inc.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: Inflation
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.